Compare Incyte Corporation (INCY) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs InMode Ltd — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while InMode Ltd trades at $15.25 (market cap $872.08M). The key difference: Incyte Corporation is far larger — about 28.1× InMode Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals.
| INCY | INMD | |
|---|---|---|
Market Cap | $24.54B | $872.08M |
Sector | Health | Technology |
52-Week High | $129.93 | $16.62 |
52-Week Low | $81.61 | $12.76 |
Enterprise Value | $20.04B | $375.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
INMD trades at $15.23, up 0.26% today, with a neutral technical outlook and mixed earnings history including a Q1 2026 miss. The company reported Q2 2026 revenue of $95.6 million, consistent year-over-year, and maintains a strong gross profit margin of 76.52%. Recent news highlights an unsolicited acquisition offer from Steel Partners at $16.75 per share and shareholder activism urging rejection, creating uncertainty around corporate governance.
The stock presents a value opportunity with low P/E and EV/EBITDA ratios, but risks include earnings volatility, potential acquisition fallout, and ongoing securities fraud investigations. Analyst consensus is divided between Buy and Hold ratings, reflecting cautious optimism amid near-term headwinds. Long-term growth depends on execution of international expansion and innovation in medical technologies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
